OncoMatch/Clinical Trials/NCT07149363
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Is NCT07149363 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Durvalumab 50 MG/ML for small cell lung cancer (sclc).
Treatment: Durvalumab 50 MG/ML — This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-L1 therapy (durvalumab)
Prior treatment with durvalumab
Cannot have received: radiation therapy
Exception: post-operative radiation for resected small cell lung cancer is acceptable in N1 disease; no other prior radiation for small cell lung cancer
No other prior radiation for small cell lung cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Virginia Comprehensive Cancer Center · Charlottesville, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify